Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert Ho

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Trends in Cancer|May 11, 2020
Amyloid Evolvability and CancerYoshiki Takamatsu, Gilbert Ho, Makoto Hashimoto
Prion|February 14, 2023
Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System AtrophyJianshe Wei, Gilbert Ho, Eliezer Masliah, et al.
Parkinson'S Disease|December 3, 2021
Therapeutic Potential of <i>α</i>-Synuclein Evolvability for Autosomal Recessive Parkinson's DiseaseJianshe Wei, Gilbert Ho, Yoshiki Takamatsu, et al.
Frontiers in Cell and Developmental Biology|July 29, 2024
Innate neuroimmunity across aging and neurodegeneration: a perspective from amyloidogenic evolvabilityGilbert Ho, Linh Lam, Tony Tran, et al.
Neoplasia (New York, N.Y.)|December 14, 2020
Adiponectin paradox as a therapeutic target of the cancer evolvability in agingYoshiki Takamatsu, Gilbert Ho, Ryoko Wada, et al.
International Journal of Molecular Sciences|April 25, 2020
Possible Role of Amyloidogenic Evolvability in Dementia with Lewy Bodies: Insights from Transgenic Mice Expressing P123H β-SynucleinMasayo Fujita, Gilbert Ho, Yoshiki Takamatsu, et al.
Drug Discovery Today|March 29, 2021
Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2Gilbert Ho, Alysha Ali, Yoshiki Takamatsu, et al.
Journal of Neurochemistry|August 10, 2006
Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathyPazit Bar-On, Edward Rockenstein, Anthony Adame, et al.
Journal of Alzheimer'S Disease Reports|May 20, 2022
Reconsideration of Alzheimer's Disease Therapy from a Viewpoint of Amyloidogenic EvolvabilityGilbert Ho, Pei Chen Choo, Masaaki Waragai, et al.
Biomolecules|March 6, 2021
Therapeutic Potential of αS Evolvability for Neuropathic Gaucher DiseaseJianshe Wei, Yoshiki Takamatsu, Ryoko Wada, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Trends in Cancer|May 11, 2020
Amyloid Evolvability and CancerYoshiki Takamatsu, Gilbert Ho, Makoto Hashimoto
Prion|February 14, 2023
Differential involvement of amyloidogenic evolvability in oligodendropathies; Multiple Sclerosis and Multiple System AtrophyJianshe Wei, Gilbert Ho, Eliezer Masliah, et al.
Parkinson'S Disease|December 3, 2021
Therapeutic Potential of <i>α</i>-Synuclein Evolvability for Autosomal Recessive Parkinson's DiseaseJianshe Wei, Gilbert Ho, Yoshiki Takamatsu, et al.
Frontiers in Cell and Developmental Biology|July 29, 2024
Innate neuroimmunity across aging and neurodegeneration: a perspective from amyloidogenic evolvabilityGilbert Ho, Linh Lam, Tony Tran, et al.
Neoplasia (New York, N.Y.)|December 14, 2020
Adiponectin paradox as a therapeutic target of the cancer evolvability in agingYoshiki Takamatsu, Gilbert Ho, Ryoko Wada, et al.
International Journal of Molecular Sciences|April 25, 2020
Possible Role of Amyloidogenic Evolvability in Dementia with Lewy Bodies: Insights from Transgenic Mice Expressing P123H β-SynucleinMasayo Fujita, Gilbert Ho, Yoshiki Takamatsu, et al.
Drug Discovery Today|March 29, 2021
Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2Gilbert Ho, Alysha Ali, Yoshiki Takamatsu, et al.
Journal of Neurochemistry|August 10, 2006
Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathyPazit Bar-On, Edward Rockenstein, Anthony Adame, et al.
Journal of Alzheimer'S Disease Reports|May 20, 2022
Reconsideration of Alzheimer's Disease Therapy from a Viewpoint of Amyloidogenic EvolvabilityGilbert Ho, Pei Chen Choo, Masaaki Waragai, et al.
Biomolecules|March 6, 2021
Therapeutic Potential of αS Evolvability for Neuropathic Gaucher DiseaseJianshe Wei, Yoshiki Takamatsu, Ryoko Wada, et al.
Pageof 3